Assessing the benefits and costs of new therapies for hepatitis B virus infection.
Owens
Douglas K
DK
Black
Martin
M
D000225:Adenine / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000191:economics* / Q000627:therapeutic use*
D000998:Antiviral Agents; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine